Sn 38g

irinotecan HCl Trihydrate injection (20 mg/mL) were purchased from Teva Parenteral Medicine, Inc. (Irvine, NY, USA) and the powder of irinotecan were purchased from Dalian Meilun Biology Technology Co., Ltd. (Dalian, China), respectively. The self-made injectable irinotecan formulation was prepared as follows: the irinotecan hydrochloride was firstly dissolved in 1,3 Propanedio by sonication 10 min, then diluted in a sorbitol/lactic acid buffer (D-sorbitol 45 mg/ml and D-lactic acid 0.9 mg/ml, pH=3.4), the control group was given 0.2 mL sorbitol/lactic acid buffer.
The reference standard irinotecan, SN-38, SN-38G, NPC, and APC were purchased from Toronto Research Chemicals Inc. (Toronto Canada). Uridine-5’- diphosphate-β, D-glucuronic acid ester, D-saccharic-1, 4-lactone monohydrate, magnesium chloride, daidzin, and astragaloside were purchased from Sigma–Aldrich Co. (St. Louis, MO, USA). Acetonitrile, methanol, and formic acid (LC-MS grade) were purchased from VWR. Glucose, Hank’s balanced salt solution (HBSS, powder form), HEPES, Ko143, MK-571, Zosuquidar (LY335979), NaHCO₃, and fetal bovine serum were purchased from Sigma-Aldrich Co., (St. Louis, MO, USA). Transwell™ cell culture insert (polycarbonate membrane and polystyrene plates with a diameter of 24 mm and a pore size of 3 μm) was obtained from Corning Incorporated (Corning, NY, USA).